Published in Pharma Law Weekly, March 1st, 2005
CMS has determined that sufficient evidence exists to conclude that an FDG PET scan for the detection of pretreatment metastases (i.e., staging) in newly diagnosed cervical cancer subsequent to conventional imaging that is negative for extra-pelvic metastasis is reasonable and necessary as an adjunct test. Further, CMS announced that it intends to issue a national coverage determination (NCD) for this indication.
CMS's final coverage decision announced recently expands the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly